Jorge Cortes, MD

Articles

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

January 14th 2025

Dr. Jorge E. Cortes provides a comprehensive overview of the 5-year follow-up results from the Phase 2 OPTIC study, showcasing the long-term efficacy, safety, and mutational analysis of ponatinib in patients with chronic-phase chronic myeloid leukemia, including outcomes related to dose modifications and mutation evolution.

Key Takeaways: The Current Landscape and Future of CML Care

January 10th 2025

Panelists discuss how it is an exciting time for chronic myeloid leukemia (CML) treatment, with many options including 6 different drugs that have been very successful for patients, which give clinicians multiple options to tailor the therapy to their patients and consider whether CML could be curable.

ASC4FIRST Trial & Asciminib New FDA Approval: Evaluating Asciminib in First-Line CML Treatment

January 10th 2025

Panelists discuss how a clinician seeks guidance on implementing asciminib in first-line chronic myeloid leukemia treatment following its FDA approval, including understanding its trial data and determining appropriate patient selection compared with existing tyrosine kinase inhibitor options.

Choosing First-Line TKI Therapy for CML: Expert Approaches to Risk Assessment & Treatment Selection

January 3rd 2025

Panelists discuss how in selecting first-line therapy for patients with newly diagnosed chronic myeloid leukemia, clinicians must carefully weigh factors including the patient’s risk score, comorbidities, drug interaction potential, monitoring requirements, and cost considerations while recognizing that available tyrosine kinase inhibitor options (imatinib, nilotinib, dasatinib, and bosutinib) have similar efficacy but distinct safety and tolerability profiles.

Managing Adverse Events: Ponatinib & Asciminib in CML: Expert Approaches

January 3rd 2025

Panelists discuss how clinicians should implement regular cardiovascular monitoring and dose modifications for ponatinib-associated toxicities while being vigilant for asciminib’s key adverse events, including thrombocytopenia, pancreatic dysfunction, and hypertension, with appropriate dose adjustments and supportive care as needed.

Dr Cortes on Asciminib’s Superior Efficacy and Safety in First-Line CML

January 2nd 2025

Jorge Cortes, MD, discusses asciminib’s sustained efficacy and improved safety over other TKIs in first-line CML.

Exploring Luspatercept's Role in Anemia Management for Lower-Risk MDS: Insights From Dr. Jorge Cortes

December 25th 2024

Jorge Cortes, MD discusses the FDA approval of luspatercept-aamt has influenced first-line MDS management.

Beyond T315I mutations: When to Consider Ponatinib or Asciminib in CML Second-Line Treatment

December 20th 2024

Panelists discuss how when choosing between asciminib and ponatinib for chronic myeloid leukemia treatment, key considerations include the patient’s mutation status, prior tyrosine kinase inhibitor therapy response, cardiovascular risk factors and comorbidities, and the differing safety profiles of the 2 drugs, with ponatinib generally having more cardiovascular concerns but broader mutation coverage vs asciminib’s more favorable tolerability but more specific targeting of BCR::ABL1.

Managing T315I Mutations in CML: Second Line Treatment Options - Ponatinib & Asciminib

December 20th 2024

Panelists discuss how for patients with chronic myeloid leukemia who develop the T315I mutation, ponatinib and asciminib have demonstrated efficacy in the PACE and ASCEMBL trials, respectively, with ponatinib showing a major cytogenetic response rate in patients with T315I mutation and asciminib demonstrating superior major molecular response vs bosutinib.

Interpreting Milestones: Prioritizing the Patient Picture

December 13th 2024

Panelists discuss how mutation analysis should be considered when treatment fails to meet milestones or patients show loss of response to tyrosine kinase inhibitor (TKI) therapy, as this information helps determine whether to continue the current TKI or switch to an alternative agent based on the specific resistance profile.

Evaluating Early Treatment Response in CML: Expert Insights on Monitoring

December 13th 2024

Panelists discuss how in standard clinical practice, response to first-line tyrosine kinase inhibitor therapy is monitored through regular molecular testing of BCR::ABL1 transcript levels, with key evaluations to assess whether patients achieve target milestone responses that predict long-term outcomes.

Drs Baljevic and Cortes Preview Upcoming Studies and Emerging Data From ASH 2024

December 6th 2024

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

Dr Cortes on the Phase 4 BYOND Study in Previously Treated Patients With CML

October 21st 2024

Jorge E. Cortes, MD, discusses efficacy and safety findings from the phase 4 BYOND study in previously treated patients with Ph+ chronic myeloid leukemia.

Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia and the T315I Mutation: 4-Year Results From OPTIC

June 18th 2024

Jorge Cortes, MD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.

Acute Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Following the ASCO 2023 and EHA 2023 Annual Meetings, experts discuss important updates in acute myeloid leukemia.

Acute Lymphoblastic Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Shared insight from key opinion leaders on clinical trial data in acute lymphoblastic leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

Chronic Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Expert perspectives on key data in chronic myeloid leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

Dr. Cortes on Defining Fitness in Patients With Hematologic Malignancies

March 24th 2023

Jorge E. Cortes, MD, discusses the importance of defining fitness in patients with hematologic malignancies prior to treatment selection.

Dr. Cortes on Better Understanding Areas of Interest in ALL

February 24th 2023

Jorge E. Cortes, MD, discusses important questions in acute lymphoblastic leukemia to address, such as improved understanding of the role of allogenic stem cell transplant and the use of tyrosine kinase inhibitor combinations.

Dr. Cortes on Emerging Therapies in CML

September 8th 2021

Jorge E. Cortes, MD, discusses emerging therapies in chronic myeloid leukemia.